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Abstract
Background: The prognostic effect of multi-component cardiac rehabilitation (CR) in the modern era of statins and
acute revascularisation remains controversial. Focusing on actual clinical practice, the aim was to evaluate the effect of
CR on total mortality and other clinical endpoints after an acute coronary event.
Design: Structured review and meta-analysis.
Methods: Randomised controlled trials (RCTs), retrospective controlled cohort studies (rCCSs) and prospective
controlled cohort studies (pCCSs) evaluating patients after acute coronary syndrome (ACS), coronary artery bypass
grafting (CABG) or mixed populations with coronary artery disease (CAD) were included, provided the index event was
in 1995 or later.
Results: Out of n¼ 18,534 abstracts, 25 studies were identified for final evaluation (RCT: n¼ 1; pCCS: n¼ 7; rCCS:
n¼ 17), including n¼ 219,702 patients (after ACS: n¼ 46,338; after CABG: n¼ 14,583; mixed populations: n¼ 158,781;
mean follow-up: 40 months). Heterogeneity in design, biometrical assessment of results and potential confounders was
evident. CCSs evaluating ACS patients showed a significantly reduced mortality for CR participants (pCCS: hazard ratio
(HR) 0.37, 95% confidence interval (CI) 0.20–0.69; rCCS: HR 0.64, 95% CI 0.49–0.84; odds ratio 0.20, 95% CI 0.08–0.48),
but the single RCT fulfilling Cardiac Rehabilitation Outcome Study (CROS) inclusion criteria showed neutral results. CR
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participation was also associated with reduced mortality after CABG (rCCS: HR 0.62, 95% CI 0.54–0.70) and in mixed
CAD populations.
Conclusions: CR participation after ACS and CABG is associated with reduced mortality even in the modern era of
CAD treatment. However, the heterogeneity of study designs and CR programmes highlights the need for defining
internationally accepted standards in CR delivery and scientific evaluation.
Keywords
Rehabilitation, acute coronary syndrome, coronary bypass grafting, coronary artery disease, mortality, hospital
readmission
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Introduction
Although several recent studies, meta-analyses1–11 and
recommendations of national and international guide-
lines12,13 suggest a beneﬁcial eﬀect of cardiac rehabili-
tation (CR) in patients with coronary artery disease
(CAD), considerable scientiﬁc doubt is still apparent
for the following reasons:
. The type of CR oﬀered varies considerably between
and within the countries with respect to content, dur-
ation, intensity and volume, and worldwide there are
no accepted minimal standards for judging the qual-
ity of CR delivery, thereby leaving doubt as to the
eﬀectiveness of CR as delivered in routine clinical
practice.14,15
. Developments within the past 20 years, including
interventional therapies, surgery and medications,
have had a large impact on the quality of care delivered
to patients who are participating in modern CR.16,17
On this basis, older studies evaluating the eﬀect of CR
are no longer suitable for estimating CR eﬀectiveness.
. In some countries, high levels of CR participation sup-
ported by government policy, health insurance, pension
funds and ethical criteria make it virtually impossible to
randomise patients out of CR, and large prospective
randomised trials on CR eﬃcacy with experimental
and highly reproducible designs are scarce.18–20
However, alternative robust research designs using rou-
tine clinical data captured through cohort studies,
observational studies and registries have been published
with ﬁndings that are worthy of consideration.3,4–9,21
For these reasons, the present study sought to assess
the actual evidence of CR’s eﬀectiveness by focusing on
CAD patients after a recent cardiac event (acute cor-
onary syndrome (ACS), coronary artery bypass graft-
ing (CABG) or mixed populations also including
patients with stable CAD) and treated in the era of
acute revascularisation during ACS and routine medi-
cation with statins. Furthermore, in order to better
reﬂect clinical practice, apart from randomised con-
trolled trials (RCTs), controlled cohort studies (CCSs)
were also included in the meta-analysis.
Methods
This systematic review was conducted and reported
according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement and the Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) statement (see
also Supplemental Material, Table SM 5).22,23 The
study protocol was prospectively published in
PROSPERO International prospective register of sys-
tematic reviews (University of York, Centre for
Reviews and Dissemination) and veriﬁed as original
(CRD42014007084).
Study eligibility criteria
The study selection criteria (populations, interventions,
controls, outcomes and designs) are outlined in detail in
Table 1. Three groups of patients were deﬁned:
a. patients after hospitalisation for ACS, including ST-
elevation myocardial infarction (STEMI), non-
STEMI (NSTEMI)orunstable anginapectoris (UAP);
b. patients after hospitalisation for CABG;
c. mixed populations including patients after ACS
and/or after CABG as a basic requirement, but
also including patients with chronic stable CAD
with or without elective percutaneous coronary
intervention (PCI).
To guarantee current CAD treatment standards
(operationally deﬁned by the Cardiac Rehabilitation
Outcome Study (CROS) as revascularisation for
acute myocardial infarction (AMI) and routine use of
statins), only studies that recruited patients in 1995 or
later were included. Total mortality was the primary
2 European Journal of Preventive Cardiology 0(00)
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endpoint. Predeﬁned secondary endpoints are outlined
in Table 1 and primarily include non-fatal cardiovascu-
lar events, hospital readmissions and mixed endpoints.
Search methods and identification of studies
Highly sensitive search strategies were developed by a
graduate information scientist (MIM) for seven
databases in order to identify two types of studies:
RCTs and CCSs, regardless of the studies’ current
status (published, unpublished, ﬁnished or ongoing).
For developing the search strategy, candidate terms
were identiﬁed (text words and controlled vocabulary)
by using a multi-stranded approach. Known key litera-
ture and the publications included in two systematic
reviews on the same topic were assessed.24,25 Fifty
Table 1. Cardiac Rehabilitation Outcome Study inclusion criteria.
Population
After ACS After CABG Mixed population
Age No restriction
Time of index events 1995 or later*
Minimal standards of acute
treatment
In-hospital standard therapy according to actual guidelines
Intervention
Multi-component CR
Start No later than 3 months after hospital discharge
Supervision CR must be under supervision and responsibility of a rehabilitation centre (centre-based CR)
Definition of
‘multi-component’
CR including supervised and structured physical exercise at least twice a week as basic requirement
plus at least one, preferably more, of the following components: information, motivational
techniques, education, psychological support and interventions, social and vocational support
CR setting In-patient, out-patient or mixed. Tele-rehabilitation will be included as long as the major part of CR
sessions is centre-based and all other predefined criteria are fulfilled
Control
Usual care
Definition Patients with index event, but not participating in CR
Patients of the control group may be supervised by general practitioners and/or resident cardiol-
ogists. They also may participate in non-structured and non-supervised exercise programmes
outside of a CR programme
Outcomes; clinical course after the index event
Primary outcome (1) Total mortality
Secondary outcomes (2) Cardiovascular mortality
(3) Major cardiovascular and cerebrovascular events (MACCE¼ combined endpoint of death,
non-fatal myocardial infarction and non-fatal stroke)
(4) Non-fatal myocardial infarction
(5) Non-fatal stroke
(6) Hospital readmission for any reason
(7) Unplanned hospital readmission for any cardiovascular event
(8) Unplanned coronary revascularization
(9) Cardiovascular mortality þ admission for any cardiovascular event
(10) All combined endpoints including fatal and non-fatal events not predefined (amendment by the
CROS steering committee, 18 January 2015)
Observation period 6 months or more after hospital discharge
Study designs and biometry
Study designs included Randomised controlled trials; prospective and retrospective cohort studies with a control group
Biometry Cohort studies must provide a description of data sources, should have used methods to reduce risk
of selection bias (e.g. linear regression analysis and propensity score methods) and should provide
information on dealing with patients lost at follow-up and missing data
*Studies including patients before and after 1995 were only included into the analysis, if the vast majority of patients was treated in 1995 or later.
CR: cardiac rehabilitation; CROS: Cardiac Rehabilitation Outcome Study.
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abstracts retrieved from PubMed using the Medical
Subject Heading (MeSH) ‘myocardial infarction/
rehabilitation’ were evaluated. All MeSH terms belong-
ing to ‘heart diseases ‘and ‘rehabilitation ‘were reviewed.
Afterwards, search blocks on two concepts were built:
‘myocardial infarction ‘and ‘coronary bypass’ for the
population of interest, and ‘rehabilitation’ as the inter-
vention under evaluation. These were then combined
with validated methodological search ﬁlters for the two
included study types.
The search strategy was elaborated for PubMed and
subsequently peer-reviewed by an independent, external
information specialist (Margaret Sampson, Childrens‘s
Hospital of Eastern Ontario, USA). After revisions
resulting from this quality assurance process, the strat-
egy was adapted to the speciﬁc requirements of each
database (syntax, search options and controlled
vocabulary). If validated search ﬁlters were not avail-
able, ﬁlters were developed for databases where ﬁltering
seemed reasonable.
Starting with the year 1995, the following biblio-
graphic databases were used with no restriction on lan-
guage: PubMed, Embase, Cochrane Central Register of
Controlled Trials, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Literatura Latino-
Americana e do Caribe em Cieˆncias da Sau´de (LILACS)
and Center for International Rehabilitation Research
Information and Exchange (CIRRIE). Additionally,
unpublished or ongoing studies were searched using the
World Health Organization’s International Clinical
Trials Registry Platform (ICTRP), a meta-register of
trials including 16 primary trial registers of diﬀerent
countries. The search was originally run in December
2013, and thereafter updated in April 2015 and again
in 22 December 2015. The details of all search strategies
are documented in the Supplemental Material (Table SM
1). The only diﬀerence between the protocol and this
review was the exclusion of the databases Current
Contents Medicine (CC MED) and Web of Science due
to the limited beneﬁts they were judged to provide.
Study selection
The selection process is outlined in Figure 1. All refer-
ences (titles plus abstracts) were independently evalu-
ated by three members of the CROS study group (BR,
CHD and PD, the ‘reference selection board’) using an
algorithm that guaranteed the independent evaluation
of each title by at least two of these experts. In addition,
the references of recent meta-analyses and potentially
eligible studies were screened. This primary selection
(PS) process was ﬁnalised by consensus within the ref-
erence selection board, resulting in n¼ 243 abstracts of
potential interest. By re-evaluating these abstracts,
n¼ 67 publications were selected for full-text
evaluation, resulting in n¼ 39 publications being
selected for a structured study evaluation (SSE). SSE
was performed and consented within an extended ref-
erence selection board (BR, CHD, PD, AS and HV),
including two biometricians (DS and KJ). In four pub-
lications, descriptions of the CR characteristics
remained incomplete despite contacting the authors
for clariﬁcation (see Tables 2 and 4a). Incomplete
description of CR characteristics did not lead to study
exclusion by decision of the reference selection board,
provided the other inclusion criteria were fulﬁlled. On
the basis of the SSE process, 25 studies remained for
meta-analysis. The primary reasons for study exclusion
at the PS level are given in Supplementary material
Table SM 2. Table SM 2 also includes studies of poten-
tial interest that were not published at the closure of the
CROS literature search.
Study evaluation process
The study evaluation included design, data sources,
information on populations, interventions, controls, cal-
culation and presentation of outcomes and handling of
bias. For RCTs, the Cochrane risk of bias table (http://
tech.cochrane.org/revman/download) was used, and for
the CCSs, the checklists of methodological issues on
non-randomised studies26 and the Newcastle–Ottawa
Scale (NOS) were used.27 In order to facilitate the
study evaluation with respect to the management of con-
founding, n¼ 8 potential confounders were prespeciﬁed,
including age, gender, smoker, diabetes, history of
stroke, history of AMI, reduced left ventricular ejection
fraction and acute or early PCI during AMI.
Data extraction
The following data were extracted from the studies that
were selected for meta-analysis: name of ﬁrst author,
year of publication, study location (country), study
design, data source, number of participants, population
(AMI, CABG or mixed), inclusion period, exclusion
criteria, mean follow-up time, mean age of participants,
gender, intervention characteristics, control character-
istics, reported outcomes, information on outcomes,
data on outcomes and covariates included in the
adjusted models.
Statistical analysis
Analyses were separately performed with regards to
population (ACS, CABG or mixed) and study design
(prospective RCT or prospective or retrospective
cohort study). For time-to-event outcomes, the hazard
ratio (HR) with its 95% conﬁdence interval (CI) was
chosen as the eﬀect measure. If possible, log HRs and
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their standard errors were extracted directly, preferably
from an adjusted model and matched-group analysis. If
these were not reported but adequate univariate ana-
lyses were available, an indirect estimation method was
used.28,29 In some publications, an odds ratio (OR) or
only absolute event numbers were reported. Therefore,
in this review, studies calculating HRs or ORs were
separately pooled and presented.28 For dichotomous
outcomes, the OR with its 95% CI was used as the
eﬀect measure. If necessary, the treatment eﬀect was
recalculated in order to be in the same direction, with
HR or OR >1.0 indicating a higher event risk for
patients participating in CR. HRs were combined
using the generic inverse-variance method. ORs were
pooled using the Mantel–Haenszel method or the gen-
eric inverse-variance method. The latter was only used
Records identified through database 
searching: n=24,610
Medline (PubMed): n=8,965
Central (Cochrane Library): n=2,178
Embase (Ovid): n=9,740
CINAHL (Ebsco): n=2,358
LILACS (iAHx): n=177 
CIRRIE: n=791
International Clinical 
Trials Registry Platform (ICTRP): n=401
Remaining records after removing 
duplicates: n=18,534
Additional records identified through non-
database sources and not included in 
databases: n=1
Non-relevant records excluded:
n=18,291
Primary selection (PS level=Studies 
potentially meeting CROS criteria): n=243
Excluded at the PS level (n=159): 
- Population:index event before 1995: n=34 
- Population: no index event as predefined 
or overlap with other studies: n=19
- Intervention: n=41
- Control: n=22
- Outcomes: n=27
- Other reasons: n=16
Ongoing studies 
of potential 
relevance: n=17
Studies selected for full text evaluation
(FTE - level): n=67 
Studies selected for structured study 
evaluation, qualitative analysis, (SSE-
level): n=39
Studies included into meta-analysis, 
quantitative analysis: n=25
Excluded at FTE level (n=28):  
- Population: index event before 1995: n=6
- Population: no index event as predefined 
or overlap with other studies of the same
group: n=8
- Intervention: n=5
- Control: n=3
- Outcomes: n=5
- Other reasons (statistics, abstract or study 
design only): n=1
Excluded at SSE level (n=14): 
- Population, index event before 1995: n=1 
- Population, no index event as predefined or 
overlap with other studies: n=6
- Intervention: n=4
- Control: n=0
- Outcomes: n=1
- Other reasons: n=2
Figure 1. Study selection flow chart.
CINAHL: Cumulative Index to Nursing and Allied Health Literature; LILACS: Literatura Latino-Americana e do Caribe em Cieˆncias da
Sau´de; CIRRIE: Center for International Rehabilitation Research Information and Exchange; PS: primary selection of extracted studies;
FTE: full-text evaluation; SSE: structured study evaluation and quality analysis according to the checklist of methodological issues on
non-randomized studies; ICTRP: International Clinical Trials Registry Platform.26
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Table 2. Studies selected for quantitative analysis; baseline study characteristics and overall results.
Study, year,
country
Study design Population:
a. Data sources
b. Number of included
participants (N)
c. Index events
d. Inclusion period
e. Other inclusion criteria
and characteristics
f. Age (y, mean SD
or as stated)
g. Gender (male, %)
Intervention:
a. Number (n)
b. Structured and
multi-component CR
(SMC-CR)?
c. Start after index event
d. Duration (time period and/or
total number of CR sessions)
e. Frequency (CR exercise
sessions per wk)
f. CR setting
Control:
a. Number (n)
b. Treatment,
characteristics
Outcome:
a. Follow-up period
b. Outcomes according
to the CROS
criteria (numbers
according to Table 1)
c. Other outcomes
Overall results with respect to
endpoints 1-10 as defined by
CROS(definitions of numbers
and correspondent endpoints
are given in Table 1)
Remarks
Boulay
et al., 2004,36
Canada
p/rCCS a. Institutional
b. n¼ 128
c. AMI
d. Probably after 1995
e. Aged 75 y, EF >35%,
first ischaemic event
f. 53.8 9.9 (CRþ, phase II)
54.3 10.3
(CRþ, phase II þ III)
56.5 9.7 (no CR)
g. 86.5 (CRþ, phase II) 78.4
(CRþ, phase II þ III) 77.8
(no CR)
a. n¼ 37 (phase II)
n¼ 37 (phase II þ III)
b. SMC-CR
c. 1 wk after discharge
(phase II)
d. 12 wk (phase II)
At least 9mo (phase III)
e. n¼ 2
f. Out-patient (phase II, III)
a. n¼ 54
b. UC, AMI within
1 y before start
of the study
a. 1 y post-AMI
b. (4), (7)
c. Number of emergency
room visits for chest
pain or suspicion for
cardiac-related
symptoms, recurrences
of fatal and non-fatal
AMI, duration of
hospital stay
Event rate (%)
Endpoint 7: No CR: 37
CRþ phase II: 29.7
CRþ phase II þ III: 16.2
p< 0.05
Endpoint 4: Control: 5.6
CR phase II: 0
CR phase IIþ III: 2.7
p< 0.05
– Different time periods
for CR and control
group (prospective and
retrospective evaluation)
– Inclusion period
confirmed by authors
Norris
et al. 2004,5
Canada
rCCS a. Data linkage: Alberta
Provincial Project
for Outcome Assessment
in Coronary Heart Disease
(APPROACH)
with the Northern
Alberta Cardiac
Rehabilitation Program
(NACRP)
b. n¼ 5081
c. Mixed population:
catheterisation for
AP and ACS, followed by PCI,
CABG or medical therapy
d. January 1995–December 1999
e. 6mo survival after index
event
f. 60.8 (CRþ) 64.2 (no CR)
g. 80.7 (CRþ) 75.2 (no CR)
a. n¼ 1470
b. SMC-CR
c. 88.65 78.09 d
Mdn 54 d (information by
author)
d. 12 wk (information by author)
e. n¼ 2–3 (information
by author)
f. Out-patient
a. n¼ 3,611
b. UC
a. 1, 2, 6 y
b. (1)
c. –
HR (95% CI)
Endpoint 1: 0.79
(0.64–0.98) in favour of CRþ
p¼ 0.036
– Description of CR
obtained by author
(continued)
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Table 2. Continued
Kutner et al.
2006,37
USA
rCCS a. United States Renal
Data System (USRDS)
b. n¼ 6215
n¼ 1855 aged <65 y
n¼ 4353 aged >65 y
n¼ 7 lost at follow-up
c. CABG
d. 1 January 1998–31
December 2002
e. HD patients surviving 90 d
post-surgery
f. 67.9 10.3 (total)
g. 61.4 (total)
a. n¼ 193 (10.4% of the
population <65 y)
n¼ 431 (9.9% of the
population >65 y)
b. Not clear, includes physical
exercise supervised or not
supervised
c .88 100 d
d. Total: 36 CR sessions
within 12 wk
e. n¼ 3
f. Out-patient
a. n¼ 5581
b. UC
a. Up to 6 y
b. (1), (2)
c. –
HR (95% CI)
Endpoint 1: 0.65
(0.56–0.76) in favour
to CRþ
p< 0.001
Endpoint 2: 0.64
(0.51–0.81) in favour
of CRþ
p< 0.001
– Description of CR
incomplete
– Multi-component CR
as defined by CROS
not witnessed
– Author contacted but
no reply
Milani et al.
2007,33
USA
rCCS a. Ochsner Medical Center,
New Orleans
b. n¼ 701
c. Coronary events, including
AMI (39%), CABG
(35%), PCI (44%)
d. January 2000–July 2005
e. Including depressive
patients
f. 64 11 (total)
g. 72 (total)
a. n¼ 522
b. SMC-CR
c. 2–6 wk after index event
d. 12 wk, total: 36 sessions
e. n¼ 3
f. Out-patient
a. n¼ 179
b. UC after non
completion
of 2 wks
CR (<5 sessions)
a. 1296  551 d
(range: 109–2,188 d)
b. (1)
c. Cardiovascular risk
factors, psychological
parameters, quality
of life
Event rate (% CRþ/no CR)
Endpoint 1: 8/30
p¼ 0.0005 (subgroup of
depressed patients)
– No mortality data from
the whole study group
(with and without
depression) available
– Contact to author not
successful
Nielsen et al.,
2008, 38
Denmark
rCCS a. Coronary care unit
at Aarhus Sygehus,
Municipality of Aarhus
cohort, Denmark,
aged 30–69 y
b. n¼ 200
c. AMI
d. 1 April 2000–31
March 2002
e. 30 d survival after AMI
f. Mdn 59.8 (CRþ) Mdn
59.7 (no CR)
g. 71.5 (CRþ), na (no CR)
a. n¼ 145
b. SMC-CR
c. 1–2 wk after hospital
admission
d. 6 wk (phase II)
e. n¼ 2 exercise sessionsþ
education, lifestyle and
psychosocial support
f. Out-patient
a. n¼ 55
b. CR
non-attenders,
UC
a. 1 and 2 y
b. (1), (4)
c. –
Event rate (% CRþ/no CR)
Endpoint 1 after 1 y: 2.1/14.5,
p¼ 0.001
Endpoint 1 after 2 y: 2.8/21.8,
p¼ 0.0001
Endpoint 4 after 1 y: 22.1/10.9,
p¼ 0.07
Alter et al.
2009,6
Canada
rCCS a. Data linkage: Toronto
Rehabilitation Institutes,
Clinical Registry (UNIX
platform), Canadian
Institute of Health
Information Discharge
a. n¼ 2,042
b. SMC-CR
c. 89 d average
d. 12mo, total: 26–36
sessions
e. n¼ 1 on-site exercise
a. n¼ 2,042
b. CR non-attenders
matched for
index events,
medical history,
age, gender,
a. 2 yþ 5.2 y (mean)
(4.0–6.6) y
b. (1) (ITT analysis)
c. Effect of CR in various
subgroups; effect of
HR (95% CI)
Endpoint 1: Total: 0.47 (0.32–
0.68); p< 0.001 65 y: 0.59
(0.35–0.97); p¼ 0.04 66 y: 0.31
(0.17–0.56); p< 0.001 high risk:
0.57 (0.36–0.90); p¼ 0.02 low
– Follow-up started
1 y after index event
(continued)
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Table 2. Continued
Abstract Database (DAD),
Ontario Health Insurance
Plan, and
Registered Persons
Database
b. n¼ 4084
c. Primary index event ACS
(97.7%), CHF and others
(2.3%)
d. 6 January 1999–10 December
2003
e. Death or readmissions within
1 y after index event
were excluded
f. 59.4 10
g. 87.4
sessionþmonitored
home-based sessions and
education
f. Out-patient
socioeconomic
status,
geographical
region; UC
CR completion and
non-completion
risk: 0.57 (0.17–1.95); p¼ 0.31
CR non-completers: 0.71
(0.29–1.71), p¼ 0.41
CR completers: 0.28 (0.13–0.60),
p< 0.001
(below 1.00 is in
favour of CRþ)
Hansen et al.
2009,34
Belgium
pCCS a. Hospital files and general
practitioners
b. n¼ 238
c. Successful CABG
d. January 1998–October 2002
e. Blanking period: 4 wk post-
CABG, exclusion: symptomatic
patients, comorbidity of
prognostic relevance
f. 65.0 9.0 (CRþ)
66.2 8.3 (no CR)
g. 69.8 (CRþ)
67.7 (no CR)
a. n ¼ 149
b. SMC-CR
c. 1–2 wk after discharge
d. 3mo, total 24 sessions
e. n¼ 3þ psychological/
educational
interventions
f. Out-patient
a. n¼ 89
b. UC
a. 2 y
b. (1), (4), (8), (10)
c. –
Event rate (% CRþ/no CR)
Endpoint 1: 0.7/5.4, p< 0.05
Endpoint 4: 0.0/3.2, p< 0.05
Endpoint 8: With PCI:
4.0/6.5
With CABG:
0.0/0.7
Endpoint 10: 4.7/14.0
– Potential selection bias
by using 2 medical
centres offering
CR or no
inclusion period from
information of the
author
Suaya et al.
2009,4
USA
rCCS a. Data linkage:
Medicare’s National
Claims History File,
Medicare’s master
enrolment database,
American Hospital
Association
b. n¼ 601,099 n¼ 70,040
matched pairs
c. Mixed population:
AMI (37.1%), CABG
(35.4%), PCI (21.0%),
others
d. Through 1997
e. age 65 y, hospital
stay 30 d,
surviving 30 d after
discharge
a. n¼ 70,040
b. SMC-CR
c. Not reported
d. Average: 24 CR sessions
Low CR users: 1–24 sessions
High CR users: 25 sessions
e. Not reported
f. Out-patient
a. n¼ 70,040
b. Non-users of CR
matched on AMI,
PCI and CABG and
demographics
a. 1þ 5 y after discharge
from index
hospitalisation
b. (1)
c. –
Event rate (% CRþ/no CR)
Endpoint 1 after 1 y:
Propensity-based matching:
2.2/5.3 Regression
modelling: 4.8/10.9
Endpoint 1 after 5 y:
Propensity-based matching:
16.3/24.6 Regression
modelling: 28.1/38.0
p< 0.0001 for all
– Description of CR is
limited to the ‘use of
CR services defined by
Medicare reimbursement
for at least 1 CR
session within 1 y of
follow-up’
– CR content is not
reported in publication
but known as
multi-component
through official
Medicare sites:
www.massgeneral.org;
http://www.massgeneral.org/
heartcenter/cardiac_rehab_
program.aspx
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Table 2. Continued
f. 6574 y: 65.2%
7584 y: 32.7% 85 y: 2.1%
g. 63.6
Ju¨nger et al.
2010,39
Germany
rCCS a. Acute Coronary
Syndrome Registry
(ACOS), including
155 hospitals in Germany
b. STEMI, n¼ 2432 NSTEMI,
n¼ 2115
c. STEMI, NSTEMI
d. June 2000–December 2002
e. Alive at hospital discharge
f. Mdn: STEMI 63.2
(CRþ) 70.0 (no CR)
NSTEMI 66.3 (CRþ) 71.3
(no CR)
g. STEMI 73.6 (CRþ); 70.0
(no CR) NSTEMI 71.5
(CRþ); 63.6 (no CR)
a. STEMI n¼ 1649
NSTEMI n¼ 1107
b. SMC-CR
c. 2 wk after hospital
discharge
d. 3–4 wk
e. 5 exercise sessions per
wkþeducation, motivation,
psychosocial support
f. In-patient
a. STEMI n¼ 783
NSTEMI n¼ 1008
b. UC (general practi-
tioner, control by
cardiologists)
a. 1 y
b. (1), (3), (10)
c. –
OR (95% CI)
Endpoint 1: STEMI: 0.41
(0.28–0.60) NSTEMI: 0.53
(0.38–0.76)
Endpoint 3: STEMI: 0.66
(0.49–0.89) NSTEMI: 0.73
(0.55–0.98)
Endpoint 10: STEMI: 0.58
(0.42–0.79) NSTEMI: 0.71
(0.53–0.97)
p< 0.001 for all calculations
– CR controlled by
German pension funds;
the numbers of exercise
sessions represent a
minimum
– Evaluation of deceased
patients: retrospective ques-
tionnaires and/or telephone
calls for assessment of CR
participation with help of
relatives, not verified by
medical records
– High risk of selection bias
Goel et al.
2011,2
USA
rCCS a. Mayo Clinic PCI
registry (Rochester
area, Olmsted County)
þ database of the Mayo
Clinic CR programme
b. n¼ 2395 n¼ 719
matched pairs
c. PCI (elective, urgent or
emergency due to ACS)
d. 1 January 1994–30
June 2008
e. –
f. 62.5 11.7 (CRþ )
66.8 13.5 (no CR)
g. 72 (CRþ) 66 (no CR)
a. n¼ 964 (entire cohort)
n¼ 719 (matched pairs)
b. SMC-CR
c. Within 3mo after
index event
d. Total: Mdn 13 sessions
e. Not reported
f. Out-patient
a. n¼ 1431
(entire
cohort)
n¼ 719
(matched pairs)
b. UC
a. Mdn 6.3 y
b. (1), (2), (4),
(8), (10)
c. –
HR (95% CI)
Propensity score stratification:
Endpoint 1: 0.53 (0.42–0.67)
p< 0.001
Endpoint 2: 0.61 (0.41–0.91)
p< 0.016
Endpoint 4: 1.07 (0.85–1.36)
p< 0.56
Endpoint 8: 1.06 (0.90–1.25)
p¼ 0.47
Endpoint 10: death, AMI, PCI,
CABG: 0.85 (0.74–0.98)
p¼ 0.022
Matched groups analysis:
Endpoint 1: 0.54 (0.41–0.71)
p< 0.001
Endpoint 2: 0.69 (0.44–1.07)
p¼ 0.095
Endpoint 4: 1.11 (0.84–1.45)
p¼ 0.47
Endpoint 8: 1.16 (0.96–1.39)
p¼ 0.13
Endpoint 10: death, AMI, PCI,
– Study includes a small sample
of patients in 1994
– Mixed population including
stable CAD patients
– No detailed description
of CR, but SMC-CR
confirmed by author
– Per definition in the study,
CR could be of low volume
– ‘Repeat PCI/CABG’ as calcu-
lated in the study was
regarded as CROS
endpoint 8
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Table 2. Continued
CABG: 0.92 (0.78–1.07)
p¼ 0.28
Kim et al.
2011,31
Korea
pCCS a. Sanggye Paik Hospital,
Seoul, Korea
b. n¼ 141
c. AMI
d. January
2006–December 2007
e. PCI or CABG,
exclusion: stroke, cancer,
neuro-musculoskeletal
symptoms
f. 61.9 10.7 (CRþ )
64.5 12.8 (no CR)
g. 71 (CRþ) 83 (no CR)
a. n¼ 69
b. SMC-CR
c. Not reported
d. 6–8 wk, hospital
monitored, followed by
monitored home based exer-
cise
e. Not reported
f. Out-patient
a. n¼ 72
b. UC
a. 1 y
b. (1), (6), (8), (10)
c. –
Event rate (% CRþ/no CR)
Endpoint 1: 1.4/1.04, p¼ 0.95
Endpoint 6: 0.0/3.0, p¼ 0.49
Endpoint 8: 6.0/10.0, p¼ 0.53
Endpoint 10: 10.0/24.0,
p¼ 0.033
– Endpoint 10 was defined as
‘recurrence’, which was a
composite of
re-hospitalisation, re-ACS,
coronary angiography, PCI,
CABG and death
– Start after index event and
CR exercise frequency not
reported
– Contact to author not
successful
Schwaab et al.
2011,32
Germany
rCCS a. Secondary selection
of participants
from the TeleGuard
trial,40
b. n¼ 1474
c. Mixed population
(AMI, stable AP,
elective or emergency
PCI, CABG)
d. 2001–2004
e. Participation in the
TeleGuard trial
f. 64.1 9.6 (CRþ)
62.2 10.3 (no CR)
g. 73.7 (CRþ) 76.9 (no CR)
a. n¼ 794
b. SMC-CR
c. 2 wk after hospital
discharge
d. 3–4 wk
e. >5 exercise sessions per
wkþ education,
psychosocial support
f. In-patient (majority)
a. n¼ 679
b. UC
a. 1 y upon CR start
b. PEP: (10) SEPs: (1),
(4), (6), (8)
c. –
Event rate (% CRþ/no CR)
Endpoint 1: 2.1/2.4, p¼ 0.014
Endpoint 4: 1.8/3.8, p¼ 0.015
Endpoint 6: 31.8/38.0, p¼ 0.013
OR (95% CI)
Endpoint 10: 0.73 (0.59–0.91)
p¼ 0.005
in favour of CRþ
– Exercise frequency is not
reported but CR follows
regulations of German
pension funds (numbers
represent a minimum as
confirmed by author)
– Self-reported CR participa-
tion, not verified
– Potential selection bias due
to 56.4% CABG patients in
the CRþ group vs. only
27.9% CABG patients in the
control group (‘no CR’)
– Suspicion of under-
representation of NSTEMI
patients in both groups
Martin et al.
2012,7
Canada
pCCS a. Data linkage: Alberta
Provincial Project
for Outcomes Assessment
in Coronary Heart
Disease (APPROACH),
Cardiac Wellness Institute
of Calgary (CWIC)
inpatient and emergency
databases; Canada
b. n¼ 5886
c. Population (ACSþ stable
AP, others)
d. 1 July 1996–31 January 2009
a. n¼ 2900 (entire
population) n¼ 2256
(matched pairs)
b. SMC-CR
c. 105.8 d (mean from
referral to CR
enrolment)
d. 12 wk, total:
21.9 10.2 sessions
e. n¼ 2–3 supervised
exercise session per
wkþ resistance
trainingþ non-supervised
a. n¼ 2986
(entire
population)
n¼ 2256
(matched pairs)
b. No CR
and non-comple-
ters of CR; UC
a. Up to 14 y
b. (1), (6), (7)
c. Emergency room
visits without
hospitalisation
HR (95% CI)
Endpoint 1: Adjusted: 0.59
(0.49–0.70) Propensity
matched: 0.67 (0.54–0.81)
Endpoint 6: CRþ completion:
0.77 (0.71–0.84) CR non-
completers: 1.30 (1.13–1.49)
Endpoint 7: CRþ completion:
0.68 (0.55–0.83) CR non-
completers: 0.87 (0.64–1.19)
– Information on CR content
not included in publication
but obtained from author
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Table 2. Continued
e. Exclusion: aged <18 y,
no official health number,
surviving <6m after
index event
f. 60.1 (CRþ) 61.1 (no CR)
g. 83.8 (CRþ) 74.7 (no CR)
sessions at home
f. Out-patient
West et al.
2012,20
UK
pRCT a. Multicentre based
b. n¼ 1813
c. AMI
d. August 1997–April 2000
e. Discharged home
within 28 d
f. 64.2 11.2 (CRþ)
64.7 10.9 (no CR)
g. 72.6 (CRþ) 74.4 (no CR)
a. n¼ 903
b. SMC-CR
c. Not reported
d. Mean: 20 h within 6–8 wk
e. n¼ 1–2 per wk
f. Out-patient
a. n¼ 910
b. UC
a. 1 y, 2 y until 7–9 y
b. (1), (4), (5), (7), (10)
c. Quality of life (SF36),
lifestyle
RR (95% CI)
Endpoint 1 after 1 y: 1.16
(0.79–1.69)
Endpoint 1 after 2 y: 0.98
(0.74–1.30)
Endpoint 1 after 7–9 y: 0.99
(0.85–1.15)
Endpoint 10 after 1 y: 0.96
(0.88–1.07)
Endpoints 4, 5, 7: no differences
between CR and control
– High risk of under-powering
– Early closure of enrolment due
to limited funding: from an
anticipated total of
6000 patients only 1813
patients were included in the
study
Beauchamp
et al. 2013,41
Australia
rCCS a. A sample of participants
of an earlier study42
b. n¼ 544
c. Mixed population: AMI,
CABG and PCI
d. 1996–1997
e. Survival within 1 y
after index event
f. 60.9 10.1 (CRþ )
64.2 12.3 (no CR)
g. 77 (CRþ) 69 (no CR)
a. n¼ 281
b. SMC-CR
c. Not reported
d. Total: 6–12 CR sessions
(each session: 1 h
exerciseþ 1 h education)
e. Not reported
f. Out-patient
a. n¼ 263
b. UC
a. 14 y
b. (1)
c. –
HR (95% CI)
Endpoint 1: 1.58 (1.16–2.15)
p¼ 0.004 in favour of CRþ
– Mortality was ascertained
through linkage to the
Australian National Death
Index
– No external validation of
clinical characteristics
– CR duration and frequency
of sessions not reported
Lee et al.
2013,43
Korea
pCCS a. Sanggye Paik Hospital,
Seoul, Korea
b. n¼ 74
c. AMI after successful
PCI with drug-eluting stent
d. November 2007–May 2009
e. Age 50–75 y excluded
if prior revascularisation,
cardiovascular or
other comorbidities
f. 58.8 10.8 (CRþ)
60.3 8.7 (no CR)
g. 81.8 (CRþ) 83.8 (no CR)
a. n¼ 37
b. Not reported
c. Within 4 wk
d. 6 wk including structured
and supervised exercise,
followed by
community-based and
self-managed exercise
(total 9mo)
e. n¼ 3 per wk
f. Out-patient
a. n¼ 37
(similar age
as CRþ)
b. UC
a. 9mo
b. (2), (4), (10)
c. Coronary
restenosis as
PEP
Event quantity (n CRþ/no CR)
Endpoint 2: 0/1, p¼ 0.33
Endpoint 4: 0/0
Endpoint 10: 1/6, p¼ 0.20
– Multi-component CR not
reported in detail
– Small numbers of study
participants
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Table 2. Continued
Marzolini
et al. 2013,44
Canada
pCCS a. Secondary analysis of
CR CARE survey
comparing CR
participation by
referral strategy
(medically stable
patients from
11 hospitals between
Windsor, Sudbury, Ottawa,
Ontario)45; linkage to medical
charts and administrative data
bases
b. n¼ 851
c. ACS
d. 2006–2008
e. Musculoskeletal
comorbidities
f. 64.8 9.7 (CRþ ) 68.1 10.6
(no CR)
g. 78.1 (CRþ) 64.7 (no CR)
a. n¼ 424
b. SMC
c. Data not available
d. Data not available
e. Data not available
f. Out-patient
a. n¼ 427
b. UC
a. Mdn: 2.7 y
b. (1), (10)
c. –
HR (95% CI)
Endpoint 1: 3.91 (1.23–12.36) in
favour of CRþ
Endpoint 10: no significant
differences
– Self-reported CR
participation
– Information on CR content
given by author; data on CR
start, duration and intensity
are not available
Pack et al.
2013,21
USA
rCCS a. Database of the
Division of Cardiovascular
Surgery, Mayo Clinic,
Rochester, including
consecutive residents
of Olmstedt County
b. n¼ 846
c. CABG
d. January 1996–December
2007
e. Exclusion if combined
procedure or discharged
to a long-term facility
f. 64.4 10.3 (CRþ)
68.3 11.0 (no CR)
g. 78 (CRþ) 73 (no CR)
a. n¼ 582
b. SMC-CR
c. Majority within 1mo
Mdn: 10 d
d. Mdn: 55 d Total:
Mdn 14 sessions
e. n¼ 3 exercise sessions
(30–45min each)þ
encouragement
to exercise for
30min/d on
‘non-CR’ days
f. Out-patient
a. n¼ 264
b. UC
a. 9.0 3.7 y
b. (1)
c. –
HR (95% CI)
Endpoint 1: 0.54
(0.40–0.74)
p< 0.001 in favour
of CRþ
– CR attendance was ascer-
tained by Mayo Clinic
database
– Patients were considered to
have participated in CR
if they attended at least 1
out-patient session within
6mo of the index CABG
surgery
Coll-Ferna´ndez
et al. 2014,46
Spain
pCCS a. Risk Factors and
Arterial Disease
(FRENA) registry,
Spain47
b. n¼ 1043
c. AMI
d. May 2003–August 2012
e. Patients with a first AMI
occurring <3mo
prior to enrolment were
considered
f. 56.0 10.0 (CRþ)
67.0 13.0 (no CR)
g. 90 (CRþ) 71 (no CR)
a. n¼ 521
b. Based on international
clinical practice
guidelines, but no
standardised protocol
for all hospitals
c. <3mo after AMI
d. Not reported
e. Not reported
f. Out-patient
a. n¼ 522
b. UC
a. Mean: 18mo
b. (1), (10)
c. –
HR (95% CI)
Endpoint 1: 0.08
(0.01–0.63)
p¼ 0.16
Endpoint 10: 0.65
(0.30–1.42)
p¼ 0.28
– Part of the information with
respect to study design was
obtained from author
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Table 2. Continued
Prince
et al. 2014,48
USA
rCCS a. Montefiore Medical
Center, New York
b. n¼ 822
c. Mixed population
(AMI, CAD, CHF,
stable AP, valvular
heart disease)
d. 1 May 2001–31
January 2011
e. –
f. 61.6 10.8 (CRþ)
61.6 12.6 (no CR)
g. 63.1 (CRþ) 58.1 (no CR)
a. n¼ 488
b. Not reported
c. Not reported
d. Not reported
e. Total (mean SD):
21.6 13.5
f. Out-patient
a. n¼ 334
b. UC
a. Up to 14 y
b. (1)
c. Predictors of CR
initiation, adherence
and completion
Endpoint 1: in favour
of CRþ , p¼ 0.0022
– Description of CR
incomplete; SMC-CR there-
fore not witnessed
– Duration of follow-up not
precisely defined
– Steps to reduce selection
bias between CRþ and no
CR are unclear
Rauch et al.
2014,8
Germany
pCCS a. OMEGA trial data base49
b. n¼ 3560
c. AMI
d. October 2003–June 2007
e. >3mo survival after
index event
f. Mdn: 62 (CRþ) 69 (no CR)
g. 76.4 (CRþ) 71.1 (no CR)
a. n¼ 2513
b. SMC-CR
c. 2 wk after hospital
discharge (according to
the German CR system,
but not witnessed
by OMEGA database)
d. 3–4 wk
e. 5 exercise sessionsþ
education, motivation,
psychosocial support
f. In-patient (vast majority)
a. n¼ 1047
b. UC
a. 4–12mo after index
event
b. (1), (2), (3), (4),
(5), (6), (8)
c. PCI/CABG, heart failure,
medication, laboratory
tests
OR (95% CI)
Endpoint 1: 0.46 (0.27–0.77)
in favour of CRþ
Endpoint 2: 0.43 (0.23–0.79)
in favour of CRþ
Endpoint 3: 0.53 (0.38–0.75)
in favour of CRþ
Endpoint 4: 0.72 (0.43–1.21)
Endpoint 5: 0.35 (0.15–0.84)
in favour of CRþ
Endpoint 6: 0.96 (0.81–1.13)
Endpoint 8: 1.00 (0.78–1.27)
– CR content and volume
controlled by German
pension funds
– Self-reported CR
participation by predefined
structured interviews
Goel K et al.
2015,3
USA
rCCS a. Institutional, Mayo
Clinic, Rochester
Minnesota
b. n¼ 201
c. CABGþ heart valve
surgery
d. 1996–2007
e. Olmsted country
residents, aged 18 y,
discharged alive
f. 71.5 9.0 (CRþ)
73.8 12.0 (no CR)
g. 78 (CRþ) 57 (no CR)
a. n¼ 94
b. SMC-CR
c. Not reported
d. 12 wk (phase II), in
addition, phase III
recommended Total:
Mdn 13
e. n¼ 1–3 per wk
f. Out-patient
a. n¼ 107
b. UC
a. 6.8 2.8 y
b. (1)
c. –
HR (95% CI)
Endpoint 1: 0.48 (0.27–0.83)
p¼ 0.009 in favour of CRþ,
adjusted for propensity
scores and mortality risk
factors
De Vries
et al. 2015,30
The Netherlands
rCCS a. Institutional, Dutch
health insurance firm,
Achmea Zorg en
Gezondheid
b. n¼ 35,919
c. ACS, and/or PCI,
CABG and/or valve
surgery
d. 1 January 2007–1
June 2010
a. n¼ 11,014
b. SMC-CR
c. Within 180 d
after index event
day. 6–12 wk
e. n¼ 2.3 exercise sessions
per wkþ education, psych-
ology, social support, physio-
therapy according to Dutch
a. n¼ 24,905
b. UC
a. 4 y
b. (1)
c. –
HR (95% CI)
Endpoint 1:
Total population:
0.65 (0.56–0.77)
p< 0.01
in favour of CRþ, adjusted
for propensity scores and
mortality risk factors
Subpopulations:
CABG/valve surgery:
– Extensive management of
confounding by automated
variable selection out of
919 potential
confounders
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Table 2. Continued
e. Aliveþ insured
365 days before and
180 d after event
f. 63.4 10.8 (CRþ)
68.1 13.2 (no CR)
g. 75 (CRþ)
58 (no CR)
guidelines
f. Out-patient
0.55 (0.42–0.74)
p< 0.01
ACS:
0.68 (0.57–0.82)
p< 0.01
Meurs
et al. 2015,50
The Netherlands
rCCS a. Secondary selection out
of two studies:
DepreMI, MIND-IT51,52
b. n¼ 1702
c. After AMI with or
without depression
d. September
1997–September 2000;
September
1999–November 2002
e. None
f. 57 10 (CRþ)
65 11 (no CR)
g. 83 (CRþ)
75 (no CR)
a. n¼ 878
b. SMC-CR
c. Mean 63 d after AMI
d. 9 wk average
e. n¼ 2.2 1.6
exercise sessions
per wk
f. Out-patient
a. n¼ 824 a. 6mo (mean)
b. (1), (6)
c. –
HR (95% CI)
Endpoint 1:
Total population:
0.83 (0.54–1.30)
p¼ 0.41
Non-depressed patients:
1.09 (0.63–1.89)
p¼ 0.74
Depressed patients:
0.48 (0.28–0.84)
p¼ 0.01
HR below 1.0 is in
favour of CRþ
– Information of CR content,
duration and intensity
obtained from author
by request
Schlitt
et al. 2015,53
Germany
rCCS a. Secondary analysis
of two RCTs with
other primary objectives54
b. n¼ 1798
c. Mixed population:
stable CAD, ACS,
CABG, heart failure others
d. 2007–2011; 2007–2009
e. >18 y, life expectancy
>12mo
a. n¼ 552
b. SMC-CR
c. Within 180 d after index
event as outlined in
publication; within 1mo
after index event like
ACS or CABG according
rules of German authorities
d. Not reported: 3–4 wk
according rules of German
authorities
e. Not reported: >5 exercise
sessions per week to be sup-
posed
f. In-patient (majority) and out-
patient
a. n¼ 1246
b. UC
a. 136 71 wk
b. (1)
c. –
HR (95% CI)
Endpoint 1:
0.067 (0.025–0.180)
p< 0.001
– High risk of selection bias,
as study is a secondary
evaluation of two RCTs
with other objectives63,64
– CR not described in detail
within the publication but
following minimal standards
given by German pension
funds and confirmed
by author
Descriptive values of metric variables are given in mean or mean plus SD, if applicable. Other calculations are noted in the table. Mdn: median; N: number of total population, n: number of subpopulation; na:
not applicable (not published); min: minute(s); h: hour(s); d: day(s); wk: week(s); mo: month(s); y: year(s).
AMI: acute myocardial infarction; AP: angina pectoris; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence interval; CR: cardiac rehabilitation;
CSS: controlled cohort study; EF: ejection fraction; EP: endpoint; HD: haemodialysis; HR: hazard ratio; HREA: hospital readmission for any reason; IG: intervention group; ITT: intention to treat; MACE:
major adverse cardiac events (death and non-fatal re-infarction); MACCE: major adverse cardiac and cerebrovascular events (death, non-fatal re-infarction and stroke); NSTEMI: non-ST-elevation myocardial
infarction; pCCS: prospective controlled cohort study; PCI: percutaneous coronary intervention; PEP: primary endpoint; rCCS: retrospective controlled cohort study; RCT: randomised controlled trial; RR:
risk ratio; SEP: secondary endpoint; SMC-CR: structured and multi-component cardiac rehabilitation; STEMI: ST-elevation myocardial infarction; UC: usual care including ambulatory supervision by family
doctor and/or cardiologist, and may also include advice to exercise at home.
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when at least one study reported an adjusted OR and
no absolute event numbers were given. Random-eﬀects
models were used to calculate overall eﬀect estimates
and conﬁdence intervals, as heterogeneity between the
‘true’ eﬀects of diﬀerent rehabilitation programmes that
were evaluated in the studies was assumed.
All of the results were checked for statistical hetero-
geneity by I2 statistics with 0–30% representing no or
only small heterogeneity, 30–60% representing moder-
ate heterogeneity, 50–90% representing substantial het-
erogeneity and 75–100% representing considerable
heterogeneity.29Due to the heterogeneous study designs
(rCCSs, pCCSs andRCTs) and statistical analysis meth-
ods (calculating either HR orOR), the number of studies
per single meta-analysis was low. A statistical evaluation
of potential publication bias based on funnel plot asym-
metry could therefore not be performed.29Nevertheless,
sensitivity analyses have been performed with respect to
extracted results of alternative analysis techniques (e.g.
independent groups instead of matched groups) and
with respect to study quality (Table SM 4,
Supplemental Material)).
Some deviations from the review protocol published
in PROSPERO have to be reported. ORs instead of
risk ratios were used as eﬀect measures for dichotom-
ous outcomes because, in some studies, adjusted ORs
and no absolute event numbers were reported. Due to
the small number of studies, a subgroup analysis, as
originally planned, was not performed. R version
3.2.2 (R Foundation for Statistical Computing, 2015)
and the R meta package version 4.3-2 (developed by
Guido Schwarzer) were used for statistical analyses.
Results
Study characteristics
Study characteristics (design, population, interven-
tions, controls and primary results) are given in
Table 2. With respect to the design, only one RCT
(n¼ 1813 patients) fulﬁlled the CROS criteria. In
addition, 17 rCCSs (n¼ 206,096 patients) and seven
pCCSs (n¼ 12,193 patients) were included. The popu-
lations predeﬁned in CROS were distributed as fol-
lows: after ACS, n¼ 12 studies (n¼ 46,338 patients);
after CABG, n¼ 5 studies (n¼ 14,583 patients); and
mixed populations, n¼ 9 studies (n¼ 158,781
patients). The CR setting was ‘out-patient’ in most
studies (n¼ 21) and predominantly ‘in-patient’
(including a variable part of ‘‘out-patient’’ CR) in
the four studies from Germany. CR duration varied
from 3–4 weeks up to 12 months, and CR intensity
varied from two up to more than ﬁve exercise ses-
sions per week plus sessions for motivation,
information, education and psychosocial interven-
tions, with variable intensities and combinations.
Meta-analysis
A summary of the clinical outcomes is given in Table 3.
The primary endpoint ‘total mortality’ was evaluated in
n¼ 22 studies, one of them evaluating both mortality
after ACS and after CABG (Figure 2).30 Participation
in CR was associated with signiﬁcantly reduced mortal-
ity in all but three studies.20,31,32 In another study, total
mortality after AMI was reduced only in depressed
patients.33
After ACS, mortality was reduced in all pCCSs by a
factor of 0.37 for patients participating in CR (n¼ 4
studies; HR 0.37, 95% CI 0.20–0.69), and heterogeneity
was low (I2¼ 17.8%). Similar results were obtained in
the rCCSs, but heterogeneity was moderate to substan-
tial. Sensitivity analyses did not change the results.
The single RCT meeting the CROS inclusion criteria
yielded a neutral result.20
After CABG, all rCCSs consistently showed
reduced mortality in patients participating in CR
(HR 0.62, 95% CI 0.54-0.70), and heterogeneity
was absent (I2¼ 0%). One additional pCCS supported
this result.34 Using independent groups instead
of matched groups in the study of Goel et al. did not
change the results substantially (HR 0.56, 95% CI
0.45–0.69).3
In ‘mixed populations’, CR participation was asso-
ciated with a signiﬁcant mortality reduction on the
basis of n¼ 5 rCCSs and n¼ 1 pCCS. The analysis of
the two rCCSs using ORs yielded a neutral result (OR
0.56, 95% CI 0.26–1.22), but heterogeneity was high
(I2¼ 81%). While the study of Suaya et al. showed a
signiﬁcant mortality reduction (OR 0.42, 95% CI 0.40–
0.45),4 the results of Schwaab et al. were neutral (OR
0.91, 95% CI 0.45–1.81).32 Sensitivity analyses did not
change the overall results.
Regarding the endpoints ‘cardiovascular mortality’
(n¼ 4 studies) and ‘major cardiovascular and cere-
brovascular events (MACCE)’ (n¼ 3 studies), only
single studies with diﬀerent populations and designs
could be identiﬁed, showing a trend in favour to CR
participation. The outcomes ‘non-fatal myocardial
infarction’ (total n¼ 6 studies) and ‘non-fatal
stroke’ (total n¼ 2 studies) did not show any
trends, and again all selected studies had diﬀerent
designs and populations.
Hospital readmission was investigated under various
conditions (endpoints 6–9) by n¼ 6 studies with diﬀer-
ent designs. A consistent and clear eﬀect of CR on hos-
pital readmissions could not be observed after ACS,
after CABG or in mixed populations.
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Table 3. Summary of results.
Outcome
Population
(number of
studies)
Design
(number of
studies)
Events/number
of patients
(CR)
Events/number
of patients
(control) HR (95% CI)
OR (95% CI);
pooling method
Heterogeneity: I2;
tau2; p-value
Total mortality ACS (10) rCCS (3) NO/10,874 NO/23,107 0.64 (0.49–0.84) 53%; 0.031
p¼ 0.12
rCCS (2) 109/2901 241/1846 0.20 (0.08–0.48); MH 77.7%; 0.615
p¼ 0.03
pCCS (4) NO/3519 NO/1993 0.37 (0.20–0.69) 17.8%; 0.092
p¼ 0.30
RCT (1) 82/903 84/910 1.01 (0.85–1.21) NA
CABG (5) rCCS (4) NO/5109 NO/5889 0.62 (0.54–0.70) 0.0%; 0.0
p¼ 0.71
pCCS (1) 1/149 5/89 0.11 (0.01–0.99); MH NA
Mixed (8) rCCS (5) NO/2606 NO/3577 0.52 (0.36–0.77) 84%; 0.145
p< 0.0001
rCCS (2) 1558/70,835 3728/70,719 0.56 (0.26–1.22); MH 81.0%; 0.267
p¼ 0.02
pCCS (1) 207/2900 315/2432 0.67 (0.55–0.82) NA
Cardiovascular mortality ACS (2) pCCS (1) 18/2505 32/1042 0.44 (0.24–0.82) NA
pCCS (1) 0/37 1/37 0.32 (0.01–8.22); IV NA
CABG (1) rCCS (1) NO/527 NO/4747 0.64 (0.51–0.81) NA
Mixed (1) rCCS (1) 34/719 46/719 0.67 (0.44–0.103) NA
MACCE ACS (2) rCCS (1) 212/2756 281/1791 0.39 (0.28–0.53); IV NA
pCCS (1) 81/2376 81/971 0.55 (0.39–0.77) NA
Mixed (1) rCCS (1) 158/785 206/1224 0.85 (0.74–0.98) NA
Non-fatal
myocardial infarction
ACS (3) pCCS (1) 0/37 0/37 1.0 (0.02–51.73); MH NA
pCCS (1) 43/2362 27/946 0.75 (0.45–1.26) NA
RCT (1) 7/162 8/115 0.60 (0.21–1.72); MH NA
CABG (1) pCCS (1) 3/343 13/334 0.22 (0.06–0.77); MH NA
Mixed (2) rCCS (1) NO/785 NO/1224 1.01 (0.74–1.37) NA
rCCS (1) 14/795 26/679 0.45 (0.23–0.87); MH NA
Non-fatal stroke ACS (2) pCCS (1) 10/2364 13/954 0.35 (0.14–0.85) NA
RCT (1) 0/162 1/115 0.23 (0.01–5.81); IV NA
Hospital readmission
for any reason
ACS (2) pCCS (2) 794/2447 351/1035 0.73 (0.23–2.34); IV 35.2%, 0.426
p¼ 0.21
Unplanned readmission
for any cardiovascular
event
ACS (2) pCCS (1) 17/74 20/54 0.51 (0.23–1.10); MH NA
RCT (1) 23/162 16/115 1.02 (0.51–2.04); MH NA
Mixed (1) pCCS (1) 32/2900 109/2432 0.68 (0.55–0.84) NA
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In n¼ 7 studies, combined endpoints with various
components were evaluated without any clear eﬀect of
CR participation. Again, these studies diﬀered with
respect to design and study population.
Quality evaluation of the studies
The quality of the cohort studies was assessed using the
NOS and the checklists of methodological issues in non-
randomised studies criteria.26,27,35 The sum of positive
adjudications estimated by NOS is given in Table 4a
(for details, see Table SM 2, supplemental material).
Four out of 24 studies were adjudicated to have 5
points or less. Limitations have been adjudicated with
respect to representativeness (n¼ 6), comparability of
the cohorts (n¼ 3), adequacy of follow-up (n¼ 5) and
the assessment of outcomes (n¼ 2).
On the basis of the checklist of methodological issues
in non-randomized studies, the following characteris-
tics were obtained: n¼ 3 studies gained their results
by secondary analysis of other clinical studies with dif-
ferent original objectives. In n¼ 2 studies, there were
either time or location diﬀerences between the study
groups. Health care decision makers and patient pref-
erences had potential inﬂuences on group formation in
most studies. Moreover, the existence of study proto-
cols was unclear in most studies, and a consort ﬂow
diagram was presented only in six out of 24 cohort
studies. Management of confounding was not reported
in n¼ 2 studies, whereas the description of potential
confounding domains was unclear or not reported in
n¼ 12 studies. Predeﬁnition and calculation of con-
founding domains as prespeciﬁed by CROS (see
‘Methods’ section) were performed to various degrees,
reﬂecting all eight predeﬁned items in n¼ 4 studies. In
contrast, n¼ 6 studies considered only three items, or
even fewer. Adjustment for confounding was per-
formed in n¼ 21 CCSs, with n¼ 3 studies not applying
adequate biometrical methods.
In the only RCT meeting the CROS inclusion cri-
teria, a high risk of under-powering has to be assumed
(Table 4b).20
Discussion
CROS is the ﬁrst review and meta-analysis evaluating
the prognostic eﬀect of structured and multi-compo-
nent CR exclusively in the era of statins and early
interventional revascularisation for acute coronary
events. Moreover, by systematically evaluating large
CCSs, CROS makes an important independent contri-
bution that more closely reﬂects the conditions in rou-
tine clinical practice. Previous systematic reviews have,
in the pursuit of increased validity, exclusively
included RCTs irrespective of publication date, withT
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Figure 2. Analysis of total mortality. Forest plots presenting the evaluation of the endpoint ‘total mortality’.
HR: hazard ratio; OR: Odds ratio; MH: Mantel–Haenszel pooling method; CR: cardiac rehabilitation; No CR: no cardiac rehabilitation
(control); CI: confidence interval; Events: number of events in the evaluated group; Total: number of patients in the evaluated group;
Start (w): start of cardiac rehabilitation after hospital discharge in weeks; Follow-up: follow-up in years.
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Table 4a. Continued
Manage-
ment of 
confounding 
at the  
analysis 
stage
Adjustment  
for confounding? 
N Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y Y Y Y 
Method § 
NA 
(a) 
(c) 
(d) 
(a) 
(d) 
(a) 
(d) 
(a) (a) 
(d) 
(e) 
(a) 
(d) 
(a) 
(b) 
(d) 
(a) 
(c) 
(b) 
(c) 
(d) 
NA (a) (a) 
(b) 
(a) NA (a) 
(c) 
(a) 
(b) 
(c) 
(d) 
(a) 
(d) 
(a) (a) 
(c) 
(d) 
(a) 
(c) 
(d) 
(a) 
(c) 
(d) 
(a) 
(d) 
(a) 
(d) 
*Specific actions to compare groups:
(1) Prospectively evaluated intervention group versus retrospectively evaluated control group.
(2) Linkage of Canadian APPROACH and NACPR registries.
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Table 4a. Continued
(3) Data extracted from the United States Renal Data System (USRDS).
(4) Retrospective identification of groups by questionnaires within a predefined study cohort.
(5) Retrospective identification of groups in a population surviving acute myocardial infarction for at least 30 days.
(6) Retrospective evaluation and formation of matched pairs.
(7) Groups were formed by two hospitals following different cardiac rehabilitation referral policies.
(8) Retrospective identification of groups by questionnaires and personal contact to relatives of deceased patients.
(9) Groups were formed prospectively according to predefined inclusion and exclusion criteria.
(10) Retrospective definition of the study groups out of an independent pre-existing study cohort on the basis of medical records.40
(11) Propensity score matching.
(12) Retrospective evaluation of a pre-existing cohort of another study evaluating cardiac rehabilitation attendance after automatic referral.
(13) Predefinition of inclusion and exclusion criteria, but final group formation by patient preferences and health care decision makers.
(14) Selection of coronary artery disease patients with musculoskeletal disease in addition.
(15) Retrospective definition of the groups; CRþ group was defined as attending at least one session within 6 months after the index event.
(16) Prospective definition of the groups out of the FRENA registry.47
(17) Patients referred for cardiac rehabilitation, but not attending served as control.
(18) Groups were pre-specified from the OMEGA trial cohort.49
(19) 180 days survival after index event required.
(20) Study population has been extracted from two pre-existent studies (DepeMI and MIND-IT).51,52
(21) Retrospective recruitment of study population from two previous randomised controlled trials not investigating cardiac rehabilitation or prognostic coronary artery disease
outcomes.53,54
yOutcomes under investigation: the numbers refer to the predefined outcomes as outlined in Table 1.
zConfounding domains as specified by CROS: 1, age; 2, gender; 3, smoker; 4, diabetes; 5, history of stroke; 6, history of acute myocardial infarction; 7, reduced left ventricular ejection fraction; 8, acute/early
percutaneous coronary intervention during acute myocardial infarction.
§Biometrical methods to manage confounding: (a) multivariable regression analysis; (b) propensity score matching; (c) propensity score-adjusted multivariable regression analysis; (d) confounders described;
(e) retrospective matched pairs. Adjusting only for age and gender has been regarded as insufficient for the limitation of confounding.
APPROACH: Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease; NACRP: Northern Alberta Cardiac Rehabilitation Program; FRENA: Risk Factors and Arterial Disease
registry (Factores de Riesgo y ENfermedad Arterial); OMEGA: Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted
Therapy after Myocardial Infarction; DepreMI: Depression after Myocardial Infarction study; MIND-IT: Myocardial Infarction and Depression Intervention Trial.
Y, yes; Y?, probably yes; N, no; N?, probably no; NC, not clear, not reported; NA, not applicable;
green  adjudication is in favour to reliability of results and reporting;
yellow  item potentially increases risk of limited reliability of results and reporting;
red  item increases risk of reliability of results and reporting.
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almost half of the studies having been performed in
the pre-statin era.1,25 During this earlier period, treat-
ment and medications were very diﬀerent compared to
clinical practice from 1995 onwards, and the impact of
CR participation on the long-term clinical course
could potentially have been attenuated through
modern treatment options.
The major ﬁnding of CROS is that CR in the mod-
ern era of cardiology is associated with signiﬁcantly
reduced total mortality after ACS and after CABG
(Table 3 and Figure 2). However, in the population
after ACS, this positive result of CCSs does not
concur with the only RCT included, which showed a
neutral result (RAMIT).20 However, the RAMIT
sample size represented, at best, 23% of the original
predeﬁned sample in each trial arm. This issue of poor
recruitment does not explain the diﬀerences in ﬁnd-
ings, but it does indicate that the results from
RAMIT may not be generalisable to a wider popula-
tion. Plausible reasons for the neutral result in
RAMIT may include super-selection of patients
ready to participate in a RCT and a variable dose of
CR compared to other trials.8,9,21,30,36
It may be criticised that within CROS, only one
RCT was included. However, this was the result of a
rigorous and targeted application of predeﬁned selec-
tion criteria (e.g. population, timing and type of CR)
(Table 1). The latest Cochrane review exclusively
including RCTs also did not show a reduction of
total mortality in the subgroup of studies published
after 1995. However, in the same review, cardiovascular
mortality was signiﬁcantly reduced in both time peri-
ods, before and after 1995.1 The variation in mode of
mortality beneﬁt between CROS (total mortality) and
the Cochrane review (cardiac mortality) is not clariﬁed,
but may be the result of diﬀerences in populations
under investigation and the type of CR delivered; for
instance, ‘exercise-only’ interventions being part of
the Cochrane analysis versus ‘multi-component’ CR
being exclusively evaluated in CROS. Such diﬀerences
in outcome from two recent meta-analyses highlight
the ongoing need for well-designed studies with speci-
ﬁed minimal standards in CR delivery and study
reporting. Moreover, these problems underscore the
need of both RCTs to prove eﬃcacy under controlled
(experimental) conditions and controlled and well-
designed observational studies in order to prove the
eﬀectiveness of such complex clinical interventions as
CR in clinical practice.
As structured and supervised exercise during CR has
been a precondition for studies to be included in CROS,
this may be regarded as the major mechanism contribut-
ing to mortality reduction. However, medical supervi-
sion, motivation, education and increased adherence to
Table 4b. Quality evaluation of randomised controlled trials included into meta-analysis (according to the
Cochrane risk of bias table; study evaluated: West et al.20).
Risk Adjudication Comments
Under-powering High risk Low recruitment (22.5% cardiac rehabilitation
arm; 22.7% control arm)
Selection bias Unclear risk Study participation influenced by patient
preferences
Random sequence selection bias Unclear risk Random sequence generation is not reported
Allocation concealment Low risk Per-protocol centrally organised randomisa-
tion and blinded with respect to baseline
characteristics
Confounding variables Unclear risk –
Performance bias Low risk Confirmation of exposure sufficient
Detection bias Low risk Cardiac rehabilitation status has been blinded
before outcome assessment
Attrition bias (incomplete outcome data) Low risk Follow-up reporting was completed in 95% of
surviving patients
Groups balanced at baseline Yes –
Groups not receiving the same baseline
treatment
Unclear risk Baseline treatment with respect to medication
and medical supervision has to be assumed;
control groups may also have received
lifestyle support to a variable extent
Intention-to-treat analysis Yes –
Reporting bias Low –
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secondary prevention medication as shown in some
included studies may also have contributed to the posi-
tive results.
No clear CR eﬀect could be demonstrated with
respect to non-fatal re-infarction and hospital readmis-
sions (Table 3). One explanation for this could be that
CR participation shifts a number of potentially ‘fatal
re-infarctions’ to ‘non-fatal’ events, thereby reducing
mortality, but not the rate of non-fatal re-infarctions.
‘Hospital readmission’ by deﬁnition is a weak clinical
endpoint, as it is exposed to a variety of eﬀectors and
potential confounders (e.g. routine control coronary
angiography in some areas, not necessarily reﬂecting
the individual‘s health condition, availability of ambu-
latory cardiologists, psychosocial confounders, etc.).
The results with respect to the remaining secondary end-
points are based on a single study or a low number of
studies, therefore not allowing us to derive suﬃciently
evidence-based conclusions (Table 3).
In summary, from the presented results, it can be
concluded that in the modern era of cardiology,
multi-component CR remains an important and eﬀect-
ive therapeutic intervention for reducing the risk of the
premature death of CAD patients, especially after an
acute event. CR therefore should be recommended as a
core part of clinical practice after ACS or following
CABG.
Limitations and strengths
Some aspects and limitations have to be considered.
a. Search strategy: while validated methodological
search ﬁlters for RCTs exist, we were not aware
of any validated methodological ﬁlters for cohort
studies. Therefore, for cohort studies, the search
ﬁlters used have not been validated so far.
b. Study quality: for a ﬁnal and conclusive estimation of
the presented outcomes, the quality evaluation of the
studies included is a basic requirement. However, the
transferability of some predeﬁned evaluation items of
the methodological checklist for reviewing non-ran-
domised trials was hampered, mainly due to the lim-
ited presentation of study protocol details in several
studies. Limitations of the studies include the pro-
cesses for group formation, information on study
protocols and CR content, missing consort ﬂow dia-
grams and management of confounding at the design
stage (Tables 4a,b). The application of the NOS did
not add signiﬁcantlymore information; rather, it con-
ﬁrmed the limitations of some of the studies (Tables
4a,b and SM3 in supplemental materials).
Heterogeneity of included studies: the CCSs included in
CROS exhibited large heterogeneity due to them being
prospective or retrospective and – as exempliﬁed by nine
studies – predominantly evaluating mixed populations,
including patients after ACS and CABG, but also stable
CAD patients in considerably varying proportions.
Heterogeneity was also noted with respect to CR dur-
ation, intensity and volume (Table 2). Whereas the end-
point of ‘total mortality’ was evaluated in n¼ 22 studies
(88%), the distribution and combination of secondary
endpoints diﬀered in every study, as did the composite
endpoints under investigation with respect to their single
components. Finally, a large variation was found with
respect to the statistical methods applied in order to
reduce confounding and the potential confounders
included in the calculations (Tables 4a,b).
Heterogeneity with respect to study designs and stat-
istical methods limits the validity of additional detailed
analysis, hence our main task was to provide least
biased and conservative eﬀect estimates. Therefore, nei-
ther diﬀerent types of eﬀect estimates nor diﬀerent
study types were pooled together, meaning that only
data based on adjusted models and matched-group
analyses were used for the primary analysis. The het-
erogeneity of the studies therefore resulted in small
numbers of studies per single meta-analysis, and evalu-
ation of potential publication bias by funnel plots was
not possible (see the ‘Methods’ section).
Heterogeneity, on the other hand, may also reﬂect the
reality of routine clinical practice, which is known to
vary between countries. This includes health care sys-
tems with diﬀerent modalities of delivering CR and dif-
ferent conditions for gaining clinical outcome data for
scientiﬁc evaluations. As these social, health economic
and political preconditions cannot be changed, clinical
science should try to balance and compensate for these
factors by deﬁning common international modalities for
study designs that are appropriate for the investigation
of multi-factorial health care interventions such as CR.
Conversely, the similarity of clinical results, such as
the reduction of mortality in CAD patients associated
with CR participation despite heterogeneous precondi-
tions, could also reﬂect the robustness of the clinical CR
eﬀect. Against this background, the criteria for multi-
component CR as deﬁned for inclusion in CROS
could, as a ﬁrst step, become the minimal requirements
(or standards) for successful CR. These standards should
consist of early CR referral after an acute event and
structured and supervised exercise at least twice a
week, with additional education sessions and psycho-
social interventions, all delivered by a multi-disciplinary
team of skilled health professionals.
Conclusions
From the basis of 24 CCSs including 217,889 patients
and reﬂecting routine clinical care in nine countries
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worldwide, participation in structured multi-component
CR is associated with reduced mortality after an acute
coronary event, even in the era of statins and acute
revascularisations. In order to achieve high-quality evi-
dence, internationally accepted minimal standards for
the planning, performing and presenting of CCSs are
warranted.
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